The landscape of pain management has shifted dramatically in 2026 with the arrival of new-generation pain relief pills that prioritize rapid, targeted relief while minimizing risks associated with traditional options like opioids. Leading the charge is suzetrigine (branded as Journavx), the first FDA-approved drug in over two decades from a novel class of non-opioid analgesics. […]